Vaccines for women age 50 and older

Emerging Infectious Diseases

Volumn 10, Issue 11, 2004, Pages 1990-1995

  Gardner, Pierce ^a,c,d   Pabbatireddy, Sudha ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c Armed Forces Epidemiological Board   (United States)

^d AMERICAN COLLEGE OF PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHICKENPOX VACCINE; DIPHTHERIA TETANUS TOXOID; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; OSELTAMIVIR; PNEUMOCOCCUS VACCINE; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ADULT; AGE; AGED; CONFERENCE PAPER; FEMALE; GENDER; HEALTH CARE PERSONNEL; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MORTALITY; NURSING HOME; SEX DIFFERENCE; STREPTOCOCCUS INFECTION; TRAVEL; UNITED STATES; VACCINATION;

EID: 7644228877     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1011.040469     Document Type: Conference Paper

References (36)

1. Centers for Disease Control and Prevention. Prevention and control of influenza. MMWR Morb Mortal Wkly Rep. 2004;53:1-40.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-86.
3. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
4. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehension strategy for eliminating transmission in the United States through universal childhood vaccination; recommendations of the Immunization practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-25.
5. Effros RB. Problems and solutions to the development of vaccines in the elderly. Immunol Allergy Clin North Am. 2003;23:41-55.
6. Fujihashi K, Koga T, McGhee JR. Mucosal vaccination and immune responses in the elderly. Vaccine. 2000;18:1675-80.
7. LeMaoult J, Szabo P, Weksler ME. Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development. Immunol Rev. 1997;160:115-26.
8. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H, et al. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1-8.
9. Hollinger FB Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 1989;87:36s-40s.
10. Gilden D: Herpes zoster with postherpetic neuralgia-persisting pain and frustration. N Engl J Med. 1994;330:932-4.
11. Levin M, Murray M, Rotbart H, Zerbe GO, White CJ, Hayward AR. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992;166:253-9.
12. Recommended adult immunization schedule-United States, 2003-2004. MMWR Morb Mortal Wkly Rep. 2003;52;965-9.
13. Centers for Disease Control and Prevention. Assessing adult vaccination status at age 50 years [notice to readers]. MMWR Morb Mortal Wkly Rep. 1995;44:561-3.
14. Patrarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, et al. Efficacy of influenza vaccine in nursing homes reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA. 1985;253:1136-9.
15. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. Presented at Options for the Control of Influenza 1986;155-68.
16. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001;154:155-60.
17. Nichol KL, Nordin J, Mullooly J, Lask R, Filibrandt K, Iwane M. et al: Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322-32.
18. Potter J, Stott DJ, Roberts MA, Elder AG, O'Donnell B, Knight PV, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients. J Infect Dis. 1997;175:1-6
19. Carman WF, Elder AG, Wallace LA, McAulay K, Walker A, Murray GD, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long term care: a randomised controlled trial. Lancet. 2000;355:93-97.
20. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2003;52(RR-13):1-8.
21. Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis. 1989;11:586-99.
22. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223-9.
23. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747-55.
24. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly a randomized, single-blind population-based trial. Am J Med. 1997;103:281-90.
25. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with Influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet. 2001;357:1008-11.
26. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among persons aged >65 years-United States, 2001. MMWR Morb Mortal Wkly Rep. 2002;51:1019-24.
27. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 1999;281:243-8.
28. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med. 2000;342:681-9.
29. Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 65 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138:960-8
30. Gardner P. A need to update and revise the pneumococcal vaccine recommendations for adults. Ann Intern Med. 2003;138:999-1000.
31. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharider conjugate vaccine. N Engl J Med. 2003;348:1737-46.
32. Centers for Disease Control. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep. 1991:40(RR-10):1-28.
33. Balestra DJ, Littenberg B. Should adult tetanus immunization be given as a single vaccination at age 65? A cost-effectiveness analysis. J Gen Intern Med. 1993;8:405-12.
34. Gardner P. Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults. In: Infectious disease clinics of North America. Vaccine recommendations: challenges and controversies. Volume 15. Philadelphia: WB Saunders; 2001. p. 143-53.
35. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, Tseng J, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98-104.
36. Centers for Disease Control and Prevention. Health information for international travel, 2003-2004. Yellow book. Atlanta: U.S. Department of Health and Human Services, Public Health Services; 2003.